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The role of the anti-apoptotic protein Bcl-2 in lung cancer remains controversial. In order to clarify its impact on survival in small and
non-small cell lung cancer (NSCLC), we performed a systematic review of the literature. Trials were selected for further analysis if
they provided an independent assessment of Bcl-2 in lung cancer and reported analysis of survival data according to Bcl-2 status. To
make it possible to aggregate survival results of the published studies, their methodology was assessed using a quality scale designed
by the European Lung Cancer Working Party (including study design, laboratory methods and analysis). Of 28 studies, 11 identified
Bcl-2 expression as a favourable prognostic factor and three linked it with poor prognosis; 14 trials were not significant. No
differences in scoring measurement were detected between the studies, except that significantly higher scores were found in the trials
with the largest sample sizes. Assessments of methodology and of laboratory technique were made independently of the conclusion
of the trials. A total of 25 trials, comprising 3370 patients, provided sufficient information for the meta-analysis. The studies were
categorised according to histology, disease stage and laboratory technique. The combined hazard ratio (HR) suggested that a positive
Bcl-2 status has a favourable impact on survival: 0.70 (95% confidence interval 0.57–0.86) in seven studies on stages I–II NSCLC; 0.50
(0.39–0.65) in eight studies on surgically resected NSCLC; 0.91 (0.76–1.10) in six studies on any stage NSCLC; 0.57 (0.41–0.78) in
five studies on squamous cell cancer; 0.75 (0.61–0.93) and 0.71 (0.61–0.83) respectively for five studies detecting Bcl-2 by
immunohistochemistry with Ab clone 100 and for 13 studies assessing Bcl-2 with Ab clone 124; 0.92 (0.73–1.16) for four studies on
small cell lung cancer; 1.26 (0.58–2.72) for three studies on neuroendocrine tumours. In NSCLC, Bcl-2 expression was associated
with a better prognosis. The data on Bcl-2 expression in small cell lung cancer were insufficient to assess its prognostic value.
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Lung cancer is the most common cause of cancer death in
industrialised countries and its incidence is steadily increasing in
women. Despite diagnostic and therapeutic improvements, the
overall 5-year survival is still less than 15% (Laudanski et al, 1999).
A prognostic factor is a variable measured in individual patients
that, alone or in combination with other factors, explains part of
the population heterogeneity, and is at the time of diagnosis able to
provide information on clinical outcome (Yip and Harper, 2000).
Some independent prognostic factors have been identified in
order to predict survival and to help in the management of patients
with lung cancer (Paesmans and Sculier, 1998). They include, for
small cell lung cancer (SCLC), extent of disease and performance
status (Paesmans et al, 2000), for resectable non-small cell lung
cancer (NSCLC) performance status, TNM stage and age (Strauss,
1997); for advanced NSCLC, performance status, TNM staging, age,
sex and weight loss (Buccheri and Ferrigno, 1994; Paesmans et al,
1995).
It has previously been reported that biological factors,
angiogenesis (measurements of number of vessels per mm
2), or
factors reflecting proliferative state (number of cells in cycle) have
a significant impact on survival in NSCLC (Kanters et al, 1995;
O’Byrne et al, 2000). Unfortunately, these are relatively crude
measures of the biological aggressiveness of the primary cancer
because they involve several metabolic pathways.
Analysis and characterisation of proteins and genes involved in
cancer development at the molecular level, could add to our
knowledge of potential prognostic factors. These factors can be
divided into categories according to their biological pathway:
tumour suppressor genes, proto-oncogenes, markers of metastatic
propensity, and proliferation markers (Strauss et al, 1995). Recent
publications have attempted to correlate survival with factors
related to angiogenesis (basic fibroblast growth factor, thrombos-
pondin, vascular endothelial growth factor), to apoptosis (Bcl-2,
p53), to control cell cycle (cyclins, MDM2, retinoblastoma gene), to
growth (epithelial growth factor, erb-B2) and some other factors
(serum lactate dehydrogenase (LDH), serum CYFRA21 level, white
blood cell count and DNA aneuploidy content). The literature
assessing their effects on survival (Strauss et al, 1995; Brambilla
et al, 1996; Pujol, 1997; Kim et al, 1998; Kwiatkowski et al, 1998;
D’Amico et al, 1999; Choma et al, 2001) remains controversial. Revised 13 February 2003; accepted 28 April 2003
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lymphoma, where a chromosomal translocation t(14:18) moves the
Bcl-2 gene into juxtaposition with transcriptional enhancer
elements of the immunoglobulin heavy chain locus. (Tsujimoto
and Croce, 1986; Aisemberg et al, 1988). In contrast, transregu-
latory mechanisms appear to be responsible for the high levels of
Bcl-2 protein production that occur in many different solid
tumours such as prostate cancer (Colombel et al, 2000), breast
cancer (Silvestrini et al, 1994) and lung cancer (Pezzella et al, 1993;
Fontanini et al, 1995). The Bcl-2 proto-oncogene is encoded by a
230kb gene. Its product, a 26kDa protein, is located in the inner
mitochondrial membrane, and to a lesser extent in cell membranes
(Jong et al, 1994). The major function of Bcl-2 appears to be to
inhibit programmed cell death (apoptosis) and to prolong cell
survival by arresting cells in the G0/G1 phase of the cell cycle. The
ratio of death antagonists (Bcl-2, Bcl-XL, Bcl-W, Mcl-1, A1) to
agonists (Bax, Bak, Bcl-Xs, Bad, Bid) determines whether a cell will
respond to an apoptotic signal. This death–life rheostat is
mediated at least in part, by competitive dimerisations between
selective pairs of antagonists and agonists (Kroemer, 1997). It is
not clear from the data currently available as to which dimers are
true regulators of apoptosis. Moreover, the possibility that at least
some dimers form part of a regulatory higher-order, multiprotein
complex cannot be excluded. The Bcl-2 protein is expressed in
foetal tissues and basal cells of human epithelia, which suggests a
role in normal growth regulation and differentiation (Hockenbery
et al, 1990; Le Brun et al, 1993).
Although there are now a large number of studies of Bcl-2
expression, their value in predicting the survival of patients with
lung cancer remains controversial. We have performed this
systematic review of the literature to assess the prognostic value
of Bcl-2 overexpression for the survival of lung cancer patients.
MATERIALS AND METHODS
Publication selection
To be eligible for inclusion in this systematic review, a study must
have been published as a full paper in the English or French
language literature and must meet the following criteria: deal with
lung cancer only; analyse patients survival according to Bcl-2
status; measure Bcl-2 expression (protein, DNA or RNA) in the
primary tumour (not in metastatic tissue or in tissue adjacent to
the tumour) and/or antibodies against Bcl-2 in the serum.
An electronic search on Medline, using the keywords ‘lung
neoplasms’ and ‘Bcl-2’, complemented by the personal bibliogra-
phy of the authors, was used to select the articles. In addition, the
bibliographies of studies already identified were used to complete
trials identification. Studies published after December 1999 were
not included.
Where the same author reported results obtained on the same
patient population in several publications, only the most recent
report, or the most complete one, was included in the analysis, in
order to avoid overlap between cohorts.
Methodological assessment
To assess methodology, 13 investigators (10 physicians, one
pathologist, one biostatistician and one biologist) read each
publication independently, and scored them according to the
ELCWP scoring scale. The scoring system used in this literature
review was used for a systematic review of the prognostic value of
p53 on survival in lung cancer and has been previously reported
(Steels et al, 2001).
Each item was assessed using an ordinal scale (possible values 2,
1, 0). The scores were compared and a consensus value for each
item was reached in meetings attended by at least two thirds of the
investigators. The participation of many readers was intended to
facilitate correct interpretation of the articles.
The score evaluates a number of aspects of methodology,
grouped into four main categories: scientific design, the descrip-
tion of laboratory methods used to identify the presence of Bcl-2
(protein, DNA/RNA or antibodies against Bcl-2), generalisability of
results and the analysis of the study data. Each category had a
maximum score of 10 points, giving a theoretical total maximum
score of 40 points. The final scores were expressed as percentages,
ranging from 0 to 100%, higher values reflecting better quality
methodology. This allowed the value of ‘not applicable’ items to be
discounted from the theoretical total of the relevant category.
Statistical methods
A study was considered as significant if the P-value for the
statistical test, comparing the survival distributions between the
groups with and without Bcl-2 expression, was o0.05 in favour of
this latter group. A study was classed as ‘positive’ when Bcl-2
expression was identified as an univariate indicator of good
prognosis for survival. Other situations, were called ‘negative’,
including the situation where a significant survival difference was
found and the group of patients who were Bcl-2-positive fared
worse.
The association between score measurements or between a score
measurement treated as a continuous variable and another
continuous variable was measured by the Spearman rank
correlation coefficient. Its significance was assessed by testing a
null hypothesis of equality to zero for this coefficient. The
comparison between score measurement according to the value
of a discrete variable was made by nonparametric Mann–Whitney
(for dichotomic variables) or Kruskal–Wallis (for nominal
variables with multiple classes) tests.
For the quantitative aggregation of the survival results, we
measured the impact of Bcl-2 positivity on survival by hazard ratio
(HR) between the survival distributions of the two Bcl-2 groups.
For each trial, this HR was estimated by a method that depended
on the results provided in the publication. The most accurate
method was to retrieve the HR estimate and its variance from the
reported results, or to calculate them directly using parameters
given by the authors for the univariate analysis: the O E statistic
(difference between numbers of observed and expected events), the
confidence interval for the HR, the log-rank statistic or its P-value.
If these were not available, we looked for the total number of
events, the number of patients at risk in each group and the log-
rank statistic or its P-value, allowing calculation of an approxima-
tion of the HR estimate. Finally, if the only useful data were in the
form of graphical representations of the survival distributions, we
extracted from them survival rates at specified times in order to
reconstruct the HR estimate and its variance, with the assumption
that during the study follow-up the number patients counted was
constant (Parmar et al, 1998). If authors reported survival of three
or more groups (e.g., using several cutoff values for percentage of
protein present in the cytoplasm, or regarding the exons of DNA
separately), we pooled the results in order to make a comparison
between two groups feasible.
Global survival of the entire patient population was analysed,
when available. If not, the results of subgroups were treated
separately. If survival was reported separately for particular
subgroups, these results were treated in the meta-analysis of the
corresponding subgroups. The same patients were never consid-
ered more than once in each analysis. The individual HR estimates
were combined into an overall HR using the method published by
Peto (Yusuf et al, 1985). By convention, an HRo1 implied a better
survival for the group with positive Bcl-2. This impact of Bcl-2 on
survival was considered as statistically significant if the 95%
confidence interval (CI) for the overall HR did not overlap 1.
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for heterogeneity, a calculation of the overall effect using a
random-effects model was also included.
The studies eligible for the systematic review were called
‘eligible’ and those providing data for meta-analysis ‘evaluable’.
RESULTS
Studies selection and characteristics
A total of 29 trials, published between 1993 and 1999, were selected
(Pezzella et al, 1993; Fontanini et al, 1995, 1996; Walker et al, 1995;
Brambilla et al, 1996; Kaiser et al, 1996; Ohsaki et al, 1996; O’Neill
et al, 1996; Rao et al, 1996; Takayama et al, 1996; Anton et al, 1997;
Apolinario et al, 1997; Higashiyama et al, 1997; Ishida et al, 1997;
Koukourakis et al, 1997; Pastorino et al, 1997; Greatens et al, 1998;
Kim et al, 1998; Kwiatkowski et al, 1998; Chen et al, 1999; D’Amico
et al, 1999; Dingemans et al, 1999; Dosaka-Akita et al, 1999; Eerola
et al, 1999; Ghosh et al, 1999; Huang et al, 1999; Laudanski et al,
1999; Maitra et al, 1999; Santinelli et al, 1999). They all report on
the prognostic value for survival of Bcl-2 status in lung cancer
patients, assessing Bcl-2 protein expression in the primary tumour.
One study was excluded because an identical patient cohort was
used in another selected publication (references excluded/
included: (Fontanini et al, 1996)/(Fontanini et al, 1995)).
The main features of the 28 studies eligible for the systematic
review are shown in Table 1. A total of 21 trials looked at NSCLC,
while SCLC and neuroendocrine tumours were studied in four and
three trials respectively. Non-small cell lung cancer trials included
either all histological subtypes (n¼17), or adenocarcinoma (n¼2)
or squamous cell cancer (n¼2). Data related to patients treated by
surgery (stages I–IIIB) comprised eight of the 21 NSCLC trials. Six
of the 21 NSCLC studies were performed in locoregional disease
(stages I–II), while seven were dealt with any stage (stages I–IV).
Immunohistochemistry techniques (IHC) were used in all the
trials to detect the expression of Bcl-2 protein. Various antibodies
were used to assess Bcl-2 expression. The two clones most used
were clones 100 and 124, in 25% (seven out of 28) and 71% (20 out
of 28) of the studies respectively.
Three of the 28 trials eligible for the systematic review reported
insufficient data for the HR to be evaluable for the quantitative
aggregation. The reasons for not including studies in the meta-
analysis were as follows: no survival curve shown (n¼1)
(Kwiatkowski et al, 1998); no P-value, HR or CI reported (n¼1)
(Greatens et al, 1998); no proportion of Bcl-2 positive (n¼1)
(Greatens et al, 1998; Dosaka-Akita et al, 1999).
Studies results report
As shown in Table 1, 11 of the 28 studies (39.3%) identified Bcl-2
expression as a good prognostic factor for survival (all evaluable
for meta-analysis), 14 (50%) concluded that Bcl-2 was not a
prognostic factor for survival (11 evaluable) and three (10.7%)
linked Bcl-2 expression with poor prognosis (three evaluable,).
Of the 21 published NSCLC trials, 11 (57.1%) were positive. All of
these studies were evaluable for meta-analysis. None of the four
studies dealing with SCLC reported significant results. One of the
three concerning neuroendocrine tumours was significant.
Evaluability status for the meta-analysis was associated with trial
positivity: the rate of positive results was 44% for evaluable trials
(11 out of 25) compared to 0% (zero out of three) for nonevaluable
ones (P¼0.26).
Quality assessment
Overall, the global quality assessment score, expressed as a
percentage, ranged between 32.9 and 79.1%, with a median of
54.6% (Table 2A where only the median values are shown). The
design subscore had the lowest values. The most poorly described
items (o30% of the maximum) were the a priori estimate of
sample size required to conduct the study, the outcome definition,
the double-blinding evaluation of the biological marker, the
reproducibility control test between the experimenters and the
initial disease work-up description.
A weak but significant correlation between the global score and
the number of patients included in the study was observed
(Spearman’s correlation coefficient r¼0.56, P¼0.0015).
No statistically significant difference was found between the 25
evaluable and the three nonevaluable studies either for the global
score (median 54.6% in comparison to 54.2%, P¼0.53 by the
Mann–Whitney test), or for the four subgroups scores.
There was also no statistically significant difference between the
global scores of 11 positive trials and the 17 negative trials (median
51.5% in comparison to 54.6%, P¼0.27 by Mann–Whitney test),
nor for their four subscores.
The score difference between the studies classified according to
the types of monoclonal antibody used was not significant. The
overall median score was respectively 59.4 and 52.1% when clone
100 or clone 124 antibodies were used (P¼0.25 by Mann–Whitney
test).
Table 2B describes the scores for the 25 trials classified as
evaluable for meta-analysis. Their overall quality score ranged
between 32.9 and 79.1%, with a median of 53.9%. There was a
significant correlation between the global score and the number of
patients included in the study (Spearman’s correlation coefficient
r¼0.55, P¼0.004). The scores of the four subgroups matched
those of the 28 studies, with the design subscore again being the
worse reported. The most poorly described items (o30% of
maximal score) were the a priori estimate of sample size required
to conduct the study, the outcome definition, the double-blinding
evaluation, the reproducibility control test between the experi-
menters, the initial disease work-up description and the number of
unassessable samples, with the reason for their exclusion. There
was no significant difference between positive and negative trials
in their global score with a median of 51.5 and 57.0% respectively
for the positive and the negative studies (P¼0.35).
The type of monoclonal antibody did not affect the overall
quality assessment, which had a median global score of 59.4% for
clone 100 and of 50.3% for clone 124 (P¼0.10).
Table 1 Main characteristics and results of the eligible studies
NSCLC
All studies Any stage Locoregional (I–II) Surgical treatment (I–III) SCLC Neuroendocrine tumours
Total S Total S Total S Total S Total S Total S
Number of studies 28 (25) 11 (11) 7 (6) 2 (2) 6 (5) 2 (2) 8 (7) 6 (6) 4 (4) 0 3 (3) 1 (1)
NSCLC¼non-small cell lung cancer; SCLC¼small cell lung cancer; S¼number of studies identifying Bcl-2 positivity as a statistically significant good prognostic factor;
()¼number of studies evaluable for meta-analysis.
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The absence of any significant qualitative difference between
positive and negative trials allowed us to perform a quantitative
aggregation of the survival data. However, only subgroup analysis
could be performed due to the heterogeneity of the trials: the trials
authors had reported on patients with different histological
subtypes (NSCLC, SCLC or neuroendocrine tumours); stages
(localised, locoregional or extensive); or treatments. The sub-
groups were defined according to histology, extent of the disease,
technique used to detect Bcl-2 (IHC with the two most frequently
used monoclonal antibodies clone 124 and 100) and the threshold
used to determine Bcl-2 positivity.
The hazard ratios were retrieved by one of the three methods
reported in the Materials and methods section. Only four studies
reported the data necessary to estimate the HR directly. In eight
trials, the HR was approximated using the total number of events
and the log-rank statistic or its P-value. For the 13 remaining
studies, the HR was extrapolated from the graphical representa-
tions of the estimated survival distributions.
In all, 28 eligible trials analysed overall survival in relation to
Bcl-2 expression in 3829 patients. Three trials were excluded and
thus the analysis was restricted to 3370 patients (88%).
Overall, Bcl-2 protein was expressed in 39% of the lung tumours
studied: 71% in SCLC, 55% in neuroendocrine tumours and 35% in
NSCLC. In the NSCLC group, 32% of the squamous cell cancer and
61% of the adenocarcinoma expressed Bcl-2. Bcl-2 expression was
found in 23, 37 and 50% respectively for the subgroups of patients
with stage I–II, surgically treated stage I–III, and any stage
disease.
The NSCLC subgroup included 18 trials comprising 2909
patients. The aggregated survival data showed a good survival
prognosis where there was Bcl-2 positivity (HR¼0.72; 95% CI
0.64–0.82).
Stages I and II NSCLC subgroup included eight trials comprising
1311 patients. The aggregation produced a statistically significant
Table 2 Methodological assessment by ELCWP score, according to trials characteristics: (A) all trials and (B) evaluable trials for meta-analysis
Global score
(%)
Design
(/10)
Laboratory
methodology (/10)
Generalisability
(/10)
Results analysis
(/10)
(A) All trials
Total (n¼28) All studies 54.6 4.0 6.1 6.7 5.0
Patient number P-value 0.0015 0.03 0.03 0.03 0.008
Evaluable for the MA (n¼25) 54.6 4.0 6.4 6.7 5.0
Not evaluable for the MA (n¼3) 54.2 5.0 7.8 6.7 5.0
P-value 0.53 0.28 0.17 0.91 0.50
Positive (n¼11) 51.5 4.0 5.7 6.6 5.0
Negative (n¼17) 54.6 5.0 7.14 6.6 5.0
P-value 0.27 0.07 0.44 0.48 0.94
IHC Ab clone 100 (n¼5) 59.4 4.0 5.0 6.7 7.5
IHC Ab clone 124 (n¼21) 52.1 4.0 6.1 6.7 5.0
P-value 0.25 0.81 0.54 0.54 0.08
(B) Evaluable trials for meta-analysis
Evaluable for the MA (n¼25) All studies 54.6 4.0 6.4 6.7 5.0
Patient number P-value 0.004 0.09 0.03 0.045 0.01
Positive (n¼11) 51.5 4.0 5.7 6.7 5.0
Negative (n¼14) 57.0 5.0 6.8 7.1 5.6
P-value 0.35 0.01 0.64 0.53 0.80
IHC Ab clone 100 (n¼5) 59.4 4.0 5.0 6.7 7.5
IHC Ab clone 124 (n¼18) 50.3 4.0 5.7 6.7 5.0
P-value 0.10 0.07 0.37 0.07 1.0
Score distributions are summarised by median values. Positive¼studies identifying Bcl-2 positivity as significant good prognostic factor for survival; negative¼studies reporting
nonsignificant results, or associating Bcl-2 positivity with poor survival; MA¼meta-analysis; IHC¼immunohistochemistry. The values in bold were significant.
Table 3 Meta-analysis of the subgroup including studies of stages I and II NSCLC with their characteristics
Group of NSCLC: stages I–II (n58)
Study Method Threshold QS (%) N Pts Bcl-2+ (%) HR 95% CI
Apolinario et al (1997) IHC-clone 100 NM 59 73 51 0.40 0.16–0.98
Chen et al (1999) IHC-clone 124 NM 33 40 43 0.18 0.04–0.88
D’Amico et al (1999) IHC-clone 120 450 72 408 23 0.88 0.60–1.28
Higashiyama et al (1997) IHC-clone 124 410 52 38 39 0.30 0.06–1.62
Koukourakis et al (1997) IHC-clone 100 NM 58 107 19 0.32 0.13–0.86
Ohsaki et al (1996) IHC-clone 124 420 50 45 29 0.45 0.13–1.56
Pastorino et al (1997) IHC-clone 120 410 76 485 17 0.89 0.65–1.21
Pezzella et al (1993) IHC-clone 100 NM 65 115 22 0.54 0.29–1.03
Overall (fixed-effects model) 1311 23 0.70 0.57–0.86
Overall (random-effects model) 0.59 0.42–0.83
w
2 statistic for heterogeneity¼12.80, 7 df, P¼0.08
IHC-clone 100¼immunohistochemistry with monoclonal antibody 100; IHC-clone 124¼immunohistochemistry with monoclonal antibody 124; QS¼Median quality score; N
pts¼number of patients; Bcl-2+¼presence of Bcl-2; df¼degree of freedom; HR¼hazard ratio; CI¼confidence interval; NM¼not clearly mentioned.
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heterogeneity was not significant (P¼0.08), but it was not possible
to go further in categorising the trials, and to treat separately
papers reporting on stage I patients. The use of a random-effects
model did not change the conclusion, with a combined HR of 0.59
(95% CI 0.42–0.83). The surgically treated NSCLC (NSCLC
completely removed by surgery for stages I–IIIB), with seven
out of eight trials evaluable, showed, a significant HR of 0.50 (95%
CI 0.39–0.65) (Table 4). Once again, the introduction of a random
effect did not change the interpretation of the HR (HR 0.50; 95% CI
0.33–0.77). The subgroup of studies including any stage NSCLC
had an HR of 0.91 (95% CI 0.76–1.10) (Table 5).
Five trials for squamous cell cancer were assessable (Table 6).
Results were significantly in favour of Bcl-2 positivity with an HR
of 0.57 (95% CI 0.41–0.78).
The NSCLC group was meta-analysed according two further
criteria: the method used to detect Bcl-2 overexpression and the
Bcl-2 positivity threshold. The aggregated results are shown in
Figures 1–6. The individual data from these studies have been
reported in Tables 3–6. Firstly, the monoclonal antibodies clones
used according to HR for the studies assessing Bcl-2 with antibody
clone 100 and clone 124 were respectively 0.75 (95% CI 0.61–0.93)
and 0.71 (95% CI 0.61–0.83). Secondly, the studies were divided
into four groups according to the definition of the threshold for
Bcl-2 positivity: global group, threshold from 1 to 20%, threshold
up to 50% and threshold not clearly described. HR, calculated by a
fixed-effect model, were respectively 0.73 (95% CI 0.64–0.82), 0.77
(95% CI 0.66–0.91), 0.65 (95% CI 0.51–0.83) and 0.62 (95% CI
0.52–0.91).
In the SCLC subgroup, four studies (all reported as negative)
comprised together 317 patients. The aggregation produced an HR
of 0.92 (95% CI 0.73–1.16) (Table 7).
For the three studies dealing with neuroendocrine tumours (86
patients), the aggregation produced an HR of 1.26 (95% CI 0.58–
2.72) (Table 8).
DISCUSSION
Our systematic review of the literature shows that overexpression
of the Bcl-2 protein is a good prognostic factor for survival in
patients with NSCLC. The analysis reveals similar features in
different subgroups of localised NSCLC and clarifies the message
of individual studies that are somewhat inconsistent.
Table 4 Meta-analysis of the subgroup including studies performed in NSCLC treated by surgery, with their characteristics
Group of NSCLC: surgical stages (n57)
Study Method Threshold QS (%) N Pts Bcl-2+ (%) HR 95% CI
Fontanini et al (1995, 1996) IHC-clone 124 41 45 89 66 0.28 0.14–0.55
Ghosh et al (1999) IHC-clone 124 450 41 134 31 0.60 0.40–0.90
Higashiyama et al (1997) IHC-clone 124 410 52 174 21 0.47 0.20–1.14
Huang et al (1999) IHC-clone 124 450 70 203 39 0.46 0.26–0.82
Ishida et al (1997) IHC-clone 124 410 64 114 38 0.23 0.06–0.86
Kim et al (1998) IHC-clone 124 NM 79 NM NM 2.50 0.90–7.1
Laudanski et al (1999) IHC-clone 124 NM 68 84 46 0.41 0.21–0.79
Overall (fixed-effects model) 798 37 0.50 0.39–0.65
Overall (random-effects model) 0.50 0.33–0.77
w
2 statistic for heterogeneity¼14.98, 6 df, P¼0.02
The meaning of the symbols is described in Table 3.
Table 5 Meta-analysis of the subgroup including studies performed in any stage of NSCLC, with their characteristics
Group of NSCLC: all stages (n56)
Study Method Threshold QS (%) N Pts Bcl-2+ (%) HR 95% CI
Anton et al (1997) IHC-clone 124 410 49 427 47 0.87 0.70–1.07
Kim et al (1998) IHC-clone 124 NM 79 238 72 1.80 1.1–2.9
O’Neill et al (1996) IHC-clone 124 41 55 54 35 1.34 0.53–3.44
Ohsaki et al (1996) IHC-clone 124 420 50 96 17 0.46 0.22–0.98
Rao et al (1996) IHC-clone 124 NM 45 41 61 0.63 0.22–1.84
Walker et al (1995) IHC-clone 124 450 46 27 44 0.18 0.03–0.97
Overall (fixed-effects model) 883 50 0.91 0.76–1.10
Overall (random-effects model) 0.85 0.53–1.37
w
2 statistic for heterogeneity¼15.34, 5 df, P¼0.009
The meaning of the symbols is described in Table 3.
Bcl-2-positive 
status better
Bcl-2-negative 
status better
Appolinario et al (1997)
D'Amico et al (1999)
Koukourakis et al (1997)
Pastorino et al (1997)
Pezzella et al (1993)
0.0 0.5 1.0 1.5 2.0
Figure 1 Hazard ratio (HR) and 95% CI of mortality in studies evaluating
Bcl-2 status by IHC with Ab 100. w
2 statistic for heterogeneity¼8.14, 4 df,
P¼0.09. NB: HRo1 implies a survival benefit for the group with positive
Bcl-2. The square size is proportional to the number of patients included in
the study. The centre of the lozenge gives the combined HR of the meta-
analysis and its extremities the 95% CI.
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methodological assessment of the publications. We have used a
methodology similar to previous systematic reviews reported by
our group on the treatment of lung cancer (Luce et al, 1998; Sculier
et al, 1998; Meert et al, 1999; Mascaux et al, 2000) after an
adaptation to biological prognostic factors such as p53 (Steels et al,
2001). By comparing the scores of the studies where Bcl-2 was a
significant prognostic factor and those where it was not, we could
identify differences, suggesting biases induced by trial methodol-
ogy. Nevertheless, our approach does not eliminate all potential
biases.
First, we have to consider publication bias. Our review took into
account only fully published studies. We did not look for
unpublished trials and abstracts because the methodology we
used required data that are usually only available in full
publications. Meta-analysis based on data on individuals is
considered by some authors as the gold standard (Stewart and
Parmar, 1993). Systematic reviews of the literature and meta-
analyses of individual patient data should not be confused. The
first approach is based only on fully published studies and
provides an exhaustive and critical analysis of the topic with an
adequate methodology based on the criteria of Mulrow (1987) and
with data aggregation (meta-analysis) when possible. The second
approach is, in fact, a new study taking in all trials performed on
the topic, whether published or not. It requires that the
investigators update individual data. In the latter case, publications
are used mainly for identification purposes. In prophylactic cranial
irradiation, our meta-analysis (Meert et al, 2001), based on the
published data, yielded the same results for patients in complete
remission as Aupe ´rin et al (1999) showed in their individual data
meta-analysis. This supports the validity of our approach.
Table 6 Meta-analysis of the studies performed in squamous cell cancer, with their characteristics
Group of squamous cell cancer (n55)
Study Method Threshold QS (%) N Pts Bcl-2+ (%) HR 95% CI
Chen et al (1999) IHC-clone 124 NM 33 40 42 0.18 0.03–0.88
Ghosh et al (1999) IHC-clone 124 450 41 134 31 0.6 0.40–0.89
Higashiyama et al (1997) IHC-clone 124 410 52 67 31 0.32 0.08–1.25
O’Neill et al (1996) IHC-clone 124 41 55 54 35 1.34 0.52–3.44
Pezzella et al (1993) IHC-clone 100 NM 65 75 27 0.42 0.20–0.91
Overall (fixed-effects model) 370 32 0.57 0.41–0.78
Overall (random-effects model) 0.54 0.33–0.89
w
2 statistic for heterogeneity¼6.67, 4 df; P¼0.15
The meaning of the symbols is described in Table 3.
Bcl-2-positive 
status better
Bcl-2-negative 
status better
0.0 0.5 1.0 1.5 2.0
Anton et al (1997)
Chen et al (1999)
Fontanini et al (1995)
Ghosh et al (1999)
Higashiyama et al (1997)
Huang et al (1999)
Ishida et al (1997)
Kim et al (1998)
Laudanski et al (1999)
O'Neill et al (1996) 
Ohsaki et al (1996)
Walker et al (1995)
Figure 2 Hazard ratio and 95% CI of mortality in studies evaluating Bcl-2
status by IHC with Ab 124. The meaning of the symbols is described in
Figure 1.
Bcl-2-positive 
status better
Bcl-2-negative 
status better
0.0 0.5 1.0 1.5 2.0
Anton et al  (1997)
Apolinario et al  (1997)
Chen et al  (1999)
D'Amico et al  (1999)
Fontanini et al  (1995)
Ghosh et al  (1999)
Higashiyama et al  (1997)
Huang et al  (1999)
Ishida et al  (1997)
Kim et al  (1998)
Koukourakis et al  (1997)
Laudanski et al  (1999)
O'Neill et al  (1996)
Ohsaki et al  (1996)
Walker et al  (1995)
Rao et al  (1996)
Pezzella et al  (1993)
Pastorino et al  (1997)
Figure 3 Hazard ratio and 95% CI of mortality in studies incorporating
NSCLC whatever the threshold of positivity chosen by the authors. The
meaning of the symbols is described in Figure 1.
Bcl-2-positive 
status better
Bcl-2-negative 
status better
0.0 0.5 1.0 1.5 2.0
Anton et al  (1997)
Fontanini et al  (1995)
Higashiyama et al  (1997)
Ishida et al  (1997)
O'Neill et al  (1996)
Ohsaki et al  (1996)
Pastorino et al  (1997)
Figure 4 Results of the meta-analysis for the subgroup of studies where
a tumour was considered as expressing Bcl-2 if 1–20% of the cells were
positive for Bcl-2. The meaning of the symbols is described in Figure 1.
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lOur review deals with studies of prognostic factors and, as
they are most often retrospective, it is much more difficult to
identify unpublished data than it is with clinical trial data.
Furthermore, we were not able to include all the papers identified
in the meta-analysis due to under-reported results, which occurred
more often in papers where an effect of Bcl-2 on survival was
not shown.
The comparison of the score of the two groups (positive and
negative trials) showed no statistically significant difference,
allowing a meaningful data aggregation. The three studies excluded
from the meta-analysis due to a lack of reported data were all
negative. There is, thus, a potential bias in favour of positive trials.
It should, however, be stressed that results were significantly better
reported in the positive studies than in the negative ones. Indeed,
studies with no statistically significant results are less often
published or, if they are published, it is with more concise reports
of results, meaning that they are more often unassessable.
Moreover, there is a language bias. We have restricted our review
to articles published in English and French, because all our readers
did not know other languages such as Japanese or German. This
bias could favour the positive studies that are more often
published in English, while the negative ones are more often
reported in native languages (Egger et al, 1997).
Another potential source of bias is related to the method for
extrapolating the HR. If they were not reported by the authors,
HR were calculated from the data available in the article and,
if that was not possible, they were extrapolated from the
survival curves, which involves making assumptions. Moreover,
there is no consensus over the choice of time intervals for reading
survival rates on the curves. Finally, we would emphasise that a
global meta-analysis did not appear meaningful because of the
heterogeneity of the patient populations. The patient population of
the studies available is very heterogeneous, often they were
restricted to patients with a specific histological subtype or a
selected tumour stage. For this reason, we did not perform a global
analysis and instead focused our analysis on more homogeneous
Bcl-2-positive 
status better
Bcl-2-negative 
status better
0.0 0.5 1.0 1.5 2.0
D'Amico et al  (1999)
Ghosh et al  (1999)
Huang et al  (1999)
Walker et al  (1995)
Figure 5 Results of the meta-analysis for the subgroup of studies where
a tumour was considered as expressing Bcl-2 if 21–50% of the cells were
positive for Bcl-2. The meaning of the symbols is described in Figure 1.
Bcl-2-positive 
status better
Bcl-2-negative 
status better
0.0 0.8 1.5 2.25 3.0
Apolinario et al  (1997)
Chen et al  (1999)
Kim et al  (1998)
Koukourakis et al  (1997)
Laudanski et al  (1999)
Rao et al  (1996) 
Pezzella et al  (1993)
Figure 6 Results of the meta-analysis for the subgroup of studies where
a tumour was considered as expressing Bcl-2 if the percentage of the cells
was not clearly mentioned positive for Bcl-2. The meaning of the symbols is
described in Figure 1.
Table 7 Meta-analysis of the studies performed in small cell lung cancer, with their characteristics
Group of SCLC (n54)
Study Method Threshold QS (%) N Pts Bcl-2+ (%) HR 95% CI
Dingemans et al (1999) IHC-clone 100 410 67 91 78 1.55 0.93–2.58
Kaiser et al (1996) IHC 450 63 146 75 0.76 0.55–1.04
Maitra et al (1999) IHC-clone 100 410 46 42 57 0.68 0.36–1.27
Takayama et al (1996) IHC-clone 124 410 55 38 55 1.31 0.64–2.70
Overall (fixed-effects model) 317 71 0.92 0.73–1.16
Overall (random-effects model) 0.99 0.66–1.48
w
2 statistic for heterogeneity¼7.35, 3 df, P¼0.06
The meaning of the symbols is described in Table 3. IHC¼Immunohistochemistry with other antibodies than clone 100 and 124.
Table 8 Meta-analysis of the studies performed in neuroendocrine tumoral lung cancer, with their characteristics
Group of neuroendocrine tumoral lung cancer (n53)
Study Method Threshold QS (%) N Pts Bcl-2+ (%) HR 95% CI
Brambilla et al (1996) IHC-clone 124 450 41 43 56 11.48 1.34–98.01
Eerola et al (1999) IHC-clone 124 NM 45 20 18 0.44 0.13–1.43
Santinelli et al (1999) IHC-clone 124 NM 49 23 61 1.81 0.57–5.77
Overall (fixed-effects model) 86 55 1.26 0.58–2.72
Overall (random-effects model) 1.71 0.35–8.41
w
2 statistic for heterogeneity¼6.79, 2 df, P¼0.03
The meaning of the symbols is described in Table 3.
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lsubgroups of patients by aggregating data from studies conducted
in similar patient populations or on similar tumours. When using
a random-effects models, we came to the same conclusions as we
did with fixed-effects models. However, such models do not
identify the source of the heterogeneity, itself an important clinical
point. It was not possible, on the basis of published data, to adjust
our results in a multivariate analysis.
Our results are based on an aggregation of data obtained by
univariate survival analysis in retrospective trials. The results need
to be confirmed by an adequately designed prospective study and
the exact value at which Bcl-2 should be considered ‘over-
expressed’ determined by an appropriate multivariate analysis
taking into account the classical well-defined prognostic factors for
lung cancer. A meta-analysis based on the individual data of the
patients included in studies (Stewart and Parmar, 1993) would help
to define by multivariate methods the prognostic role of Bcl-2, but
it would require the collection of a huge amount of retrospective
data, with the potential problem of dealing with a lot of missing
data. But such a study could never have the equivalent value of a
well-designed prospective study (Cappelleri et al, 1996).
Another possible source of confusion is the use of same cohort
of patients for different publications (Fontanini et al, 1996). If the
same patients are included twice or more in a meta-analysis, it may
give a higher weighting to these studies. In the systematic review,
we have excluded the studies for which it was possible to identify
with certainty that similar patients cohorts had been used in
different publications (Fontanini et al, 1995). On the other hand,
when the data in the publication did not allow us to decide if the
same cohort of patients was being investigated (Pezzella et al, 1993;
Koukourakis et al, 1997), we have assumed that the authors have
been sufficiently honest not to re-report the results from the same
cohort of patients without making this clear in the paper.
Finally, for practical purposes, and because of their small
number, we have included in the negative group the three trials
that showed that of the presence of Bcl-2 had a significant negative
effect on survival.
The techniques used to identify overexpression of Bcl-2 status
can also be a potential source of bias. The IHC used to reveal the
Bcl-2 protein is not always performed with the same antibody.
Sometimes the protocol was performed without prior reaction of
epitope unmasking on fixed issue (Cattoretti et al, 1993). To try to
exclude technical biases, we performed subgroup analysis accord-
ing to the most frequently used methods: IHC with antibody clone
100 and clone 124 (Figures 1 and 2). In both cases, the results were
consistent with a favourable survival in the case of Bcl-2
overexpression, making it improbable that the techniques were a
source of bias. Moreover, the cutoff in the number of positive cells
defining a tumour with Bcl-2 overexpression is often arbitrary and
varies according to the investigators, from a few percent to 50%.
The use of different cutoff points for IHC is of critical importance,
as was shown by Lee et al (1995). Some investigators selected the
cutoff point based on the minimum P-value approach, which can
lead to seriously biased conclusions (Altman et al, 1994). If a
chosen cutoff is often arbitrary, selection according to the median
value of expression levels provides a more standardised approach
to prognostic factors, although it may lead to some loss of
information (Altman et al, 1994). An optimal threshold still needs
to be defined for Bcl-2.
It should be noted that the four eligible studies reporting on
SCLC and two of the three studies concerning neuroendocrine
tumours were negative. In fact, it is very difficult to draw a definite
conclusion because of the small number of patients included in
these trials. Consequently, further studies are necessary to
determine the value of Bcl-2 as a prognostic factor for survival
in SCLC and in neuroendocrine tumours.
In our systematic review with meta-analysis, patients with
Bcl-2-positive tumours had significantly better survival than
those with Bcl-2-negative tumours. The mechanism underlying
the effect of Bcl-2 oncoprotein expression on tumour progression
and prognosis remains essentially uncertain. Originally, the
Bcl-2 gene product was implicated in oncogenesis because of its
ability to prolong cell survival through the inhibition of apoptosis
(Adams and Cory, 1998; Antonsson and Martinou, 2000). The
process of apoptosis involves many proteins such as the
antiapoptotic proteins (Bcl-2, Bcl-X, Bfl-1) and the proapoptotic
proteins (Bax, Bak, Bad) (Kroemer, 1997). These proteins can
interact in order to regulate cellular apoptosis by balancing
pro- and antiapoptotic mechanisms. Thus, the study of only one
apoptotic protein produces an incomplete appraisal of apoptosis
and it would be interesting to conduct a survival analysis
of a combination of these proteins. Moreover, the distribution
of Bcl-2 protein observed in normal tissues and embryonic
tissues indicates that it has a function in morphogenesis linked
to cell proliferation via escape from cell death (Le Brun et al, 1993;
Adams and Cory, 1998; Antonsson and Martinou, 2000). In
NSCLC, Fontanini et al (1995) stated that Bcl-2 oncoprotein
expression status was not correlated with proliferative potential
indicators including PCNA and Ki-67. On the other hand,
considering how rarely extrathoracic metastasis in NSCLC express
Bcl-2, it could be proposed that this oncoprotein plays an
inhibitory role in the haematogenous metastatic process through
tumour progression. The question of whether Bcl-2 oncoprotein
biologically participates in the haematogenous metastatic process
and reduces the incidence of distant metastasis has still to be
elucidated.
In conclusion, our systematic review of the lung cancer
literature suggests that overexpression of Bcl-2, in patients with
NSCLC has good prognostic value for survival, whatever the
biological test used. This observation is potentially important.
Identification of independent prognostic factors allows us to define
high-risk patients for whom specific therapy may be designed or to
introduce stratification in randomised trials. In lung cancer, the
prognostic factors currently used are clinical variables such as
performance status or disease extent. The results of our meta-
analysis, which suggest a relation between Bcl-2 and survival,
should encourage properly designed prospective studies, with an
appropriate statistical methodology including multivariate analy-
sis, in order to demonstrate the usefulness of molecular biological
markers like Bcl-2, assessed by IHC.
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